144 ·Filed Jun 11, 2026

QURE

uniQure N.V.
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago SEC0001973379-26-000234
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a pre-planned sale under a 10b5-1 program with no urgent signal. Monitor the subsequent Form 4 filing to confirm execution. The small size relative to market cap suggests no material market impact.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d ⚠ clustered
QURE ▲ +65.69% at T+60d
NEUTRAL call ✓ call won +65.69% · α vs SPY +62.42% · entry $27.57 → $45.68
Entry anchored
Jun 11, 03:59 PM ET
via exchange tick
T+1d
+1.09%
call +1.09% · α -0.68%
$27.87
settled 4mo ago
T+5d
+67.90%
call +67.90% · α +67.23%
$46.29
settled 4mo ago
T+20d
+54.62%
call +54.62% · α +52.84%
$42.63
settled 3mo ago
T+60d
+65.69%
call +65.69% · α +62.42%
$45.68
settled 24d ago

Price Chart

Loading chart...

Executive Summary

Director Balachandran Madhavan filed a Form 144 indicating intent to sell 11,993 ordinary shares of uniQure N.V. via Citigroup Global Markets, with an aggregate market value of approximately $324,578. The sale is tied to restricted stock unit vesting and a stock option exercise under a Rule 10b5-1 trading plan adopted on March 16, 2026. The transaction is small relative to the $1.7B market cap and appears routine.

Key Facts

  • Director Balachandran Madhavan intends to sell 11,993 ordinary shares.
  • Aggregate market value of proposed sale: $324,577.59.
  • Sale includes 7,970 shares from RSU vesting and 10,000 shares from stock option exercise.
  • The option exercise and sale are executed under a 10b5-1 plan adopted March 16, 2026.
  • Filing date: June 11, 2026; broker: Citigroup Global Markets, Inc.

Financial Impact

Sale of 11,993 shares valued at ~$324,578, representing about 0.02% of market cap.

dilution (minimal)insider holdings

Risk Factors

  • Insider sales can sometimes precede negative news, but the 10b5-1 plan reduces that risk.
  • No other material risks identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001973379-26-000234
Document: 0001973379-26-000234-index.html0001973379-26-000234
Document: 0001973379-26-000234.txt0001973379-26-000234
32 reports for QURE
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +27.15%Jul 29, 2026
Filters
Rows
Reports for QURE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BULLISH ★ 7/10
$46.23 $44.47▼ −3.81%▼ −2.85%$23.46 (−49.25%)
Jul 29, 2026
9w ago
8-K
BULLISH ★ 8/10
$40.07 $44.24▲ +10.41%▲ +4.88%$23.46 (−41.45%)
Jul 7, 2026
12w ago
Insider Cluster
BEARISH ★ 5/10
$41.41 $41.52▼ −0.27%▲ +0.29%$23.46 (+43.35%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 4/10
$41.81 $44.48▼ −6.39%▼ −5.46%$23.46 (+43.89%)
Jul 2, 2026
13w ago
Insider Cluster
MIXED ★ 5/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jul 2, 2026
13w ago
144
NEUTRAL ★ 2/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 2/10
$45.17 $41.41▼ −8.32%▼ −8.59%$23.46 (−48.06%)
Jun 25, 2026
14w ago
144
BEARISH ★ 5/10
$47.51 $41.81▲ +12.00%▲ +14.16%$23.46 (+50.62%)
Jun 24, 2026
14w ago
424B5
MIXED ★ 6/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (64h 59m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access